HBYH(SZ:000422)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥4,718,236,820.44, a decrease of 14.59% compared to ¥5,524,494,999.24 in the same period last year[6] - Net profit attributable to shareholders was ¥220,099,824.27, down 65.52% from ¥638,334,832.84 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥207,258,135.00, a decline of 65.28% compared to ¥596,921,626.18 in the previous year[6] - Basic and diluted earnings per share were both ¥0.2451, reflecting a decrease of 65.52% from ¥0.7109 in the previous year[6] - The weighted average return on equity was 4.33%, down 19.08% from 23.41% in the same period last year[6] - The net profit for Q1 2023 was CNY 278,534,690.96, a decrease of 63.4% compared to CNY 761,390,611.18 in Q1 2022[35] - The net profit attributable to shareholders of the parent company was CNY 220,099,824.27, down 65.5% from CNY 638,334,832.84 in the same period last year[35] - Operating profit for the current period is approximately $294.40 million, a significant decline of 64.0% compared to $819.14 million in the previous period[46] Cash Flow - The net cash flow from operating activities was ¥954,629,881.77, which is 13.08% lower than ¥1,098,251,279.11 in the same period last year[6] - Cash received from other operating activities decreased by 69% compared to the same period last year, mainly due to the recovery of inter-company funds from Hunan Yihua Chemical Co., Ltd. in the previous year[23] - Cash paid for various taxes decreased by 58% compared to the same period last year, mainly due to a decrease in income and corresponding payable taxes[23] - Cash received from investment income decreased by 100% compared to the same period last year, mainly due to the recovery of investment funds from Xinjiang Yihua Chemical Co., Ltd. in the previous year[23] - The company reported a net cash outflow from financing activities of CNY -243,981,436.21, an improvement from CNY -650,736,014.50 in the previous year[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥20,030,709,887.37, an increase of 1.85% from ¥19,666,579,120.58 at the end of the previous year[6] - Total liabilities increased to CNY 12,965,023,353.71, up from CNY 12,857,711,176.57, reflecting a growth of 0.84%[33] - The total equity rose to CNY 7,065,686,533.66, an increase of 3.76% from CNY 6,808,867,944.01[33] - Current liabilities increased to approximately 2.16 billion, up from 2.02 billion at the beginning of the period[32] Investments and Projects - The company plans to invest in a 100,000 tons/year refined phosphoric acid project, with a capital increase of ¥97.02 million to its subsidiary[14] - The company plans to collaborate on a 100,000-ton refined phosphoric acid project with a subsidiary, indicating a strategic expansion in production capacity[40] - The company provided financial assistance totaling CNY 100 million to its subsidiary, with a loan interest rate of 3.2% for a term of 12 months, supporting operational funding needs[41] Other Financial Metrics - Investment income increased by 570% compared to the same period last year, mainly due to increased investment income from Xinjiang Yihua Chemical Co., Ltd.[23] - Other income increased by 43% compared to the same period last year, mainly due to an increase in government subsidies[23] - Sales expenses increased to approximately $28.44 million, up 42.3% from $20.01 million in the previous period[46] - Research and development expenses decreased to approximately $145.12 million, down 12.2% from $165.37 million in the previous period[46] - The company recorded investment income of approximately $180.54 million, a substantial increase from $26.93 million in the previous period[46]